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Bile acidsPeroxisome biogenesis and peroxisomal β-oxidation defects are rare inherited metabolic disorders in
which several organs can be affected. A panel of mouse models has been created in which genes crucial
to these processes were inactivated and the ensuing pathologies studied. In mice with enzyme defects of
peroxisomal β-oxidation, the disease state strongly depends on the kind of substrates that are metabolized
by the enzyme and the dietary composition. Because mice with generalized biogenesis defects seldom
reach adulthood, conditional knockout models were generated to study the consequences of peroxisome
deﬁciency in hepatocytes, different brain cell types and Sertoli cells. Although the precise relationship
between the biochemical anomalies and pathologies was often not resolved, the mouse models allowed
to document in detail histological abnormalities, metabolic and gene expression deregulations some of
which are mediated by PPARα, and to uncover the essential role of peroxisomes in some unsuspected
cell types. This article is part of a Special Issue entitled: Metabolic Functions and Biogenesis of peroxisomes
in Health and Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Besides their role in peroxide metabolism, peroxisomes do cata-
lyze other reactions which are of utmost importance for human
health. The absence of functional peroxisomes as occurring in the
inherited disorder, Zellweger syndrome (ZS) is indeed lethal. Because
in ZS and in other related disorders, the biogenesis of peroxisomes
is affected, these diseases are classiﬁed as peroxisome biogenesis de-
ﬁciencies (PBD). Some patients with a defective peroxisomal
β-oxidation considerably phenocopy the PBDs, suggesting that
β-oxidation is an essential peroxisomal process in man. In order to in-
vestigate the pathogenic mechanisms of these peroxisomal diseases a
number of mouse models were generated. In the ﬁrst part of this re-
view we will discuss the phenotypes of mice with a defect in peroxi-
somal β-oxidation enzymes and in the second part, the consequences
of ablation of functional peroxisomes in different organs in postnatal
life. For the developmental abnormalities in PBDmice we refer to pre-
vious overviews [1-3].lic Functions and Biogenesis of
lism, Faculty of Pharmaceutical
823, B-3000 Leuven, Belgium.
. Baes).
rights reserved.1.1. Peroxisome biogenesis
In mice, as in other mammals, peroxisome biogenesis is controlled
by various proteins encoded by Pex genes. For recent reviews, we
refer to [4,5] and the chapter by Waterham and Steinberg in this
issue [6].
Brieﬂy, we can distinguish PEX proteins that are necessary to form
a membrane, and PEX proteins that play a role in import of matrix
and/or membrane proteins. In the absence of functional PEX3p,
PEX16p or PEX19p, no peroxisomal remnants can be found. When
the defect is located in other PEX genes, one can see remnants of per-
oxisomes, either without content (ghosts) or missing a selective set of
matrix proteins. These matrix proteins are synthesized in the cytosol
and are decorated with a targeting sequence. The most common is a
C-terminal tripeptide, or upon more extended analysis a dodecapep-
tide [7], called SKL or PTS1, which is recognized by the cytosolic
PEX5p receptor, and this complex is subsequently bound by the dock-
ing protein PEX14p and translocated into the organelle. For proper
functioning of PEX5p (recycling, ubiquitination), various other PEX
proteins are needed (PEX1p, PEX6p, PEX2p, PEX10p, PEX12p). Anoth-
er targeting signal can be found near the N-terminus of some matrix
proteins, a nonapeptide, recognized by PEX7p. This complex interacts
with the long isoform of PEX5p, and docks at the same site as
the PTS1/PEX5p complex. PTS2 is present on only three pro-
teins, thiolase (ACAA1), phytanoyl-CoA α-hydroxylase (PHYH), and
alkyl-dihydroxyacetone-phosphate synthase (ADAPS), catalyzing a
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ether lipid synthesis respectively. Patients with a PEX5p deﬁciency
or a defect in a PEX protein acting downstream of PEX5p, belong to
the Zellweger spectrum diseases. Mutations in PEX7p result in a
distinct phenotype, named rhizomelic chondrodysplasia punctata
(RCDP).
1.2. Peroxisomal β-oxidation
As described in more detail in a recent review [8], mammalian
peroxisomes handle a large set of carboxylic substrates. Best known
are very long chain fatty acids (VLCFA), 2-methylbranched fatty
acids, pristanic acid being the best documented one, bile acid inter-
mediates, polyunsaturated fatty acids (PUFA), eicosanoids, dicarbox-
ylic medium chain fatty acids and xenobiotics.
These substrates need to be activated to CoA esters (see chapter by
Watkins) [9] and, either before or after activation, to be transported
inside peroxisomes. It is generally assumed that three ABCD-
transporters mediate this translocation (see chapters by Imanaka
and by Kemp et al.) [10,11].
Inside peroxisomes, acyl-CoAs are ﬁrst dehydrogenated, a process
catalyzed by at least three different acyl-CoA oxidases: ACOX1, of
which two isoforms (type a and b) exist, ACOX2, and ACOX3
(Fig. 1). ACOXL (ACOX4) is likely another member of this family,
but maybe not functional in man (Van Veldhoven P.P., unpublished
data). During this reaction hydrogen peroxide is produced which is
neutralized by catalase. Subsequently, the trans-2-enoyl-CoAs are hy-
drated to 3-hydroxyacyl-CoA, with either an L- or D-conﬁguration, via
respectively multifunctional protein 1 (MFP1) or MFP2 (also known
as D-bifunctional protein, D-BP and HSD17B4). The 3-hydroxyacyl-
CoA dehydrogenase domains of these MFPs convert the 3-hydroxy-  ACOX2
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Fig. 1. Overview of peroxisomal β-oxidation. At the right side, steps and enzymes involved in
are normally derived from isoprenoids like phytol and cholesterol (double arrow indica
α-oxidation is racemic. At the left side, the pathway for substrates without a 2-methylbr
blue. Dashed arrows do indicate minor pathways.acyl-CoA to 3-oxo-acyl-CoA. These are ﬁnally cleaved by CoA-
depending thiolases. In mice this step is carried out by either one of
the two isoforms of ACAA1 or by sterol carrier protein (SCP)x. The lat-
ter thiolase, which contains a C-terminal SCP2 domain, is encoded by
the Scp2 gene which also codes for the cytosolic/peroxisomal 14 kDa
lipid carrier SCP2 [12].
To which extent acyl-CoAs are handled selectively or primarily by
one of the different enzymes catalyzing each β-oxidation step, de-
pends largely on their structure (chain length, the presence of a 2-
methylgroup or other substituents, the bulkiness of the ω-end). For
compounds with a 2-methyl group (pristanic acid, bile acid interme-
diates), the enzymes are ACOX2, MFP2 and SCPx. ACOX3 is also able
to oxidize pristanoyl-CoA, but so far it has not been shown to be ac-
tive in mouse. Based on the biochemical abnormalities in patients or
mouse models (see further), VLCFA are handled preferentially by
ACOX1 (isoform b), MFP2 and both ACAA1 and SCPx; PUFA by
ACOX1, MFP2 and both thiolases; dicarboxylic acids by ACOX1, both
MFPs, and SCPx; prostanoids by ACOX1 and MFP2. Related to 2-
methylbranched substrates, only one isomer (methylgroup in the
2S-conﬁguration) can be desaturated by the involved acyl-CoA oxi-
dases (ACOX2 or ACOX3). The other isomer can be converted, at the
level of the CoA-ester, by 2-methylacyl-CoA racemase (AMACR).
This enzyme, containing two targeting signals, is not only present in
peroxisomes, but also in mitochondria. In addition to this set of
basic enzymes, peroxisomes can convert unsaturated carboxylates
to the proper form by additional enzymes [8], but no mouse models
related to these enzymes are yet available.
The products of β-oxidation are acetyl-CoA (or propionyl-CoA in
case of 2-methylbranched substrate) and a shortened acyl-CoA. In-
deed, in contrast to the situation in mitochondria, peroxisomal β-
oxidation does not go to completion: bile acids undergo only onecholesterol
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tes multiple steps). In contrast to bile acid intermediates, pristanic acid formed via
anch is shown. Enzymes, that have been deleted in mouse models, are displayed in
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converted, either to carnitine esters by carnitine acyltransferases
(CRAT and CROT), to acids by acyl-CoA hydrolases (ACOT8,
ACOT12), or to amides in the case of C24 bile acid CoA-ester by a con-
jugating enzyme (BAAT). Except for ACAA1, all the enzymes men-
tioned above contain a PTS1 and are imported via PEX5p.
The cofactors required for peroxisomal β-oxidation are FAD
(ACOX), NAD+ (MFP), CoA (thiolases) and NADPH (DECR). However,
not much is known how these are taken up by the organelles [13].
One integral membrane protein, PMP34, belonging to the family of
solute transporters, is clearly associated with peroxisomes. It is
thought, based on the properties of the yeast orthologue, to be in-
volved in ATP-transport [14] or to be a transporter for multiple free
cofactors in and out of peroxisomes [15]. PMP22, another PMP,
forms a pore with an exclusion limit of 600 Da allowing access of neu-
tral solutes up to 300 Da (see chapter by Hiltunen and Antonenkov
[16,17]).
2. Mouse models with peroxisomal β-oxidation deﬁciencies
During the last decade, various mouse models were generated in
which a single enzyme of the peroxisomal β-oxidation was ablated
(Table 1). For some of these models the corresponding human disease
is known (see Ferdinandusse and Wanders) [18]. The others might
provide clues for the human phenotype. In addition, a few double
knockout mouse models were created, either missing both a β-
oxidation enzyme and PPARα, missing two β-oxidation enzymes or
in which a β-oxidation defect is combined with impaired plasmalo-
gen synthesis (Table 1).
2.1. ACOX1
ACOX1 deﬁcient mice [19] do in fact lack both ACOX1 isoforms.
The mice display growth retardation and are infertile due to a marked
depletion of Leydig cells [20]. Blood levels of VLCFA (C26:0) are in-
creased, suggesting that ACOX2 cannot take over the desaturation of
the CoA-esters or that the enzyme is inhibited by accumulatingTable 1
List of mouse models with peroxisomal β-oxidation enzyme defects.
Affected gene Affected protein Symptoms Biochemical a
Amacr Racemase Normal but intolerant
to phytol loading
C27 bile acid p
pristanic acid
Acox1 acyl-CoA oxidase,
isoform a and b
Growth retardation
infertility
hepatosteatosis in
adult life
Plasma VLCFA
plasma DHA ↘
liver VLC-PUF
Echhadh MFP1 Normal
Hsd17b4 MFP2 Growth retardation
infertile
testis degeneration
neurodegeneration
Impaired prist
impaired bile
C27 bile acid p
VLCFA ↗
testis VLC-PUF
MFP2+MFP1 Hypotonic
postnatal death (1/3)
VLCFA ↗
C27 bile acid p
MFP2+DHAPAT Hypotonic
postnatal death
Plasmalogen d
brain DHA↘
brain VLCFA↗
Acaa1 Thiolase B Normal PUFA ↗
response PPAR
Scp2 SCPx/SCP2 Intolerant to phytol
loading
Impaired prist
impaired bile
C27 bile acid p
pristanic acid/
SCPx Pristanic acid/
Pxmp2 PMP22 Normal Altered osmot
Slc25a17 PMP34 Normal but intolerant to
phytol loading
Pristanic acid/ACOX1 substrates. Plasma levels of arachidonic (C20:4) and docosa-
hexaenoic acid (C22:6) are however decreased [21]. In addition to
VLCFA, in liver VLC-PUFA (C24–30; ﬁve to six double bonds) accumu-
late [22]. During the ﬁrst months of adulthood, hepatic steatosis de-
velops and peroxisome assembly is compromised in the fatty cells.
In older animals (6–7 months), foci of regenerated cells with sponta-
neous peroxisome proliferation are observed in the liver. This leads ﬁ-
nally to development of hepatic adenomas and carcinomas (at
15 months of age) [23]. Peroxisome proliferation is absent in Acox1/
Pparα knockouts [24] indicative that endogenous PPARα ligands are
metabolized by ACOX1. Furthermore, it was hypothesized that dicar-
boxylic acyl-CoAs accumulate, because their formation is enhanced
by induction of CYP4A10 by PPARα upregulation, and their degrada-
tion is prevented by absence of peroxisomes. These DCAs could dam-
age the mitochondria, impair mitochondrial β-oxidation and cause
steatosis [24].
Recently, the age related liver problems were linked to ER stress
mediated by sustained PPARα activation [25]. This causes overex-
pression of the transcriptional regulator p8, the promoter of which
contains PPAR response elements, leading to an increase in ER
stress-related effectors. The sustained p8 activation and unfolded
protein response signaling trigger apoptosis and cell proliferation.
By adenoviral transfer, (human) ACOX1a and/or b were reintro-
duced [21] in the Acox1 knockout mouse. Although expression is tran-
sient and mainly limited to liver, it reverses the hepatic phenotype.
Type b isoform is more effective (but also higher expressed) to re-
store the phenotype, the plasma C22:6 levels, the production of nervo-
nic acid (C24:1), and to suppress the PPARα activation. Normalization
of the ACOX1 phenotype was also seen after introduction of the
human ACOX gene via transgenic techniques [25]. In this case
human ACOX1 was expressed in most tissues.
2.2. MFP1
Mice lacking MFP1 (also known as L-bifunctional protein) are via-
ble, fertile, and do not exhibit a particular defect [26]. Also no PPARα
activation was observed, and response to PPARα activators wasbnormalities Human counterpart References
recursors ↗
↗ (phytol diet)
Racemase deﬁciency
(adult onset sensorimotor
neuropathy)
[49]
↗
A↗
Acox1 deﬁciency
(pseudoneonatal
adrenoleukodystrophy)
[19-25]
Not diagnozed yet [26,27]
anic acid oxidation
acid oxidation
recursors ↗
A ↗
MFP2/D-BP deﬁciency [27,30,31,33,34]
recursors ↗
[35,36]
eﬁciency [37]
?
Not diagnozed yet [46-48]
anic acid oxidation
acid oxidation
recursors ↗
phytanic acid ↗ (phytol diet)
SCPx deﬁciency [38,39,41,42]
phytanic acid ↗ (phytol diet) [43]
ic behaviour of peroxisomes Not diagnozed yet [17]
phytanic acid ↗ (phytol diet) Not diagnozed yet Van Ael et al.,
Unpublished
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phenotype is attributed to the presence of MFP2. In vitro this enzyme
can handle all 2-enoyl-CoA substrates used by MFP1, although form-
ing another 3-hydroxyacyl-CoA isomer. Bile acid synthesis, as
expected, was normal [27]. In cultured mouse hepatocytes lacking
MFP1, breakdown of both saturated medium chain [28] and polyun-
saturated long chain dicarboxylic acids [29] is impaired.
2.3. MFP2
Deﬁciency of MFP2 (also called d-bifunctional protein and estradi-
ol dehydrogenase type IV, encoded by the Hsd17b4 gene but further
denoted asMfp2 knockout for reasons of clarity) has a pronounced ef-
fect in mice. Although indistinguishable at birth, the animals become
severely growth retarded and about one third dies before weaning
[30]. Surviving mice develop progressive motor deﬁcits, become im-
mobile and die at 6 months [31]. Biochemically, the abnormalities in-
clude impaired breakdown of VLCFA and bile acid intermediates.
Degradation of dicarboxylic fatty acids in hepatocytes was normal
[28]. As expected, C27 bile acid intermediates carrying a desaturated
side chain were found in bile [30], but C24 bile acids are still formed.
Possibly these are generated via a path involving MFP1 (hydratation
of 24E-enoyl-CoA to 24S,25S-isomer), AMACR and MFP1 (dehydroge-
nation of 24S,25R-isomer) (Fig. 1) [32]. Alternatively, C24 bile acids
can be formed from brain-derived 24S-hydroxycholesterol, which
can be shortened via MFP1. In young pups, the accumulating C27
bile acid intermediates were mainly unconjugated, likely causing
poor growth during lactation [27]. Starting from 10 days on, the con-
jugation enzyme is markedly induced so that after weaning, taurine
conjugates are accumulating [27].
Upon phytol feeding, pristanic acid and phytanic acid accumulate
in liver triglycerides [30]. The increase in phytanic acid is probably
secondary to the defect in pristanic acid breakdown. Upregulation of
PPARα target enzymes is observed in liver, suggesting a role of
MFP2 in removal of endogenous ligands [30,33].
In a selective set of tissues of Mfp2 knockout mice, including reti-
na, cerebellum and testis neutral lipid accumulation is observed
[31,34]. In brain, the lipid accumulations are seen in the ependymal
cells and the molecular layer of the cerebellum. Given no lesions in
the peripheral nerves, the motor impairment is linked to damage in
the CNS. Astrogliosis and reactive microglia is mainly observed in
the gray matter of brain and spinal cord. Although no major demye-
lination was observed in corpus callosum [31], more detailed studies
revealed variable myelin deﬁcits and axonal damage in cerebellum
and brain stem (Verheijden and Baes, unpublished observations).
Surprisingly, brain lesions are not exacerbated by an increase in
branched fatty acids (via phytol feeding), suggesting that another
MFP2 substrate is involved. As no shortage of DHA was found in
brain, also a lack of these products of peroxisomal β-oxidation could
be eliminated as a cause of neuropathology.
MFP2 deﬁciency affects spermatogenesis already in prepuberty. In
Sertoli cells, a marked accumulation of neutral lipids (triglycerides
and cholesteryl esters) is evident, evolving to a complete testicular at-
rophy at 4 months [34]. Testicular fatty acid analysis revealed a re-
duction in docosapentaenoic acid (C22:5), the mouse counterpart of
C22:6, formed via peroxisomal β-oxidation, and increased levels of
VLC-PUFAs. The lipid abnormalities in testis, being still present in
Mfp2/Pparα double knockouts [34] are not mediated by PPARα.
When both MFP2 andMFP1 are missing, half of the pups are hypo-
tonic, resembling a generalized peroxisome deﬁciency. Although sim-
ilar amounts of C26:0 accumulated in brain lipids as in Pex5 knockout
mice, no neuronal migration defects were found [35]. Bile acid syn-
thesis was more affected than in Mfp2 knockout mice, conﬁrming
the hypothesis that MFP1 can contribute to bile acid side chain short-
ening. Intriguingly, the MFP1/MFP2 deﬁcient livers lost the ability to
import peroxisomal proteins [27,36] as also observed in ACOX1deﬁciency and displayed mitochondrial abnormalities, as observed
in hepatocytes lacking functional peroxisomes (see below).
To investigate the consequences of coinciding defects in peroxi-
somal β-oxidation and plasmalogen synthesis, as occurs in ZS, Mfp2
and Gnpat mouse lines were crossbred. Mfp2/Gnpat knockout pups
do not show a cortical neuronal migration defect [37] as in PEX5 de-
ﬁcient mice [2]. However, they are hypotonic at birth, always die in
the postnatal period [37] and thus are more severely affected than ei-
ther of the knockouts separately. This is suggestive of a reinforcing ef-
fect of plasmalogen shortage and peroxisomal β-oxidation deﬁcits,
which is however not responsible for migratory defects. Maturation
of the cerebellum is delayed, but this is also observed in Gnpat
knockouts.2.4. SCPx deﬁciency
Mice lacking sterol carrier protein-x (SCPx) were generated by
Seedorf et al. (strain C57BL/6) [38], and later by Atshaves et al. [39]
(strain C57BL/6NCr). Interpretation of their phenotype is somewhat
complicated by the fact that also SCP2 is missing in these animals.
SCP2 might play a role in cytosolic transport of lipids, including cho-
lesterol, as well as intra-peroxisomal transport of α- or β-oxidation
intermediates. Despite these multiple postulated functions, Scpx/
Scp2 knockout mice develop normally. However, it cannot be exclud-
ed that certain functions of SCP2 are taken over by other proteins con-
taining this domain (e.g. MFP2) or that other lipid binding proteins, as
shown for FABP [38], are upregulated. Spontaneous peroxisome pro-
liferation is seen in liver of Scpx/Scp2 knockout mice. VLCFA are nor-
mal, implying that SCP2 is not essential for the transport of VLCFA
or their CoA esters towards or in peroxisomes. In serum and tissues,
phytanic acid levels are higher [38] although one should expect pris-
tanic acid accumulation. The apparent less active α-oxidation has
been ascribed to the absence of SCP2, shown to bind phytanoyl-CoA
with high afﬁnity [38], possibly facilitating transport of phytanoyl-
CoA to and in peroxisomes. Another explanation is that SCP2 facili-
tates the presentation of substrates to the hydroxylase [40]. When
given phytol, serum phytanic acid is further raised and also pristanic
acid levels are elevated. Consistent with the role of SCPx, increased
levels of β-oxidation intermediates such as 2E-pristenic acid and 3-
hydroxypristanic acid were demonstrated in saponiﬁed liver extracts.
Whereas a low dose of phytol (b2.5 mg/g) results in body weight re-
duction and hypolipidemia, higher doses (5 mg/g) lead to liver dis-
ease, inactivity, ataxia and peripheral neuropathy, followed by death
after three weeks [38]. Heart functions are impaired in these mice
(severe bradycardia and abnormal conduction), likely causing sudden
death. It is thought that the acccumulation of phytanic acid in the
myocardial membranes is responsible for the cardiac problem [41].
Increased levels of unusual bile acid intermediates are found in
Scpx/Scp2 knockout mice, but the majority of bile acids in bile are
still C24 bile acids [42] suggesting alternative routes to degrade C27
bile acid intermediates. More detailed analysis of bile revealed the
presence of a 24-oxo-C26 bile alcohol [42]. This compound is probably
formed by the spontaneous decarboxylation of 3,7,12-trihydroxy-24-
oxo-cholestanoyl-CoA, the substrate of SCPx. Furthermore, norcholic
and nordeoxycholic acid are found in serum. It is assumed that
these C23 bile acid species are formed by α-oxidation from their nor-
mal C24-counterparts. The relative abundance of these aberrant bile
acids is much higher in serum than in bile, indicative that they are
less efﬁciently conjugated and secreted in bile.
Absence of SCPx/SCP2 results in small changes in hepatic lipids
and their composition: lower cholesterolesters and triglyceride
pools [38], less phosphatidylcholine and cholesterol [39] more phos-
phatidylethanolamine, phosphatidylserine, and GM1 [39]. This re-
duces the ﬂuidity of lipid rafts prepared from isolated hepatic
plasma membranes [39].
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expressing SCP2 (strain C57BL/6NCr) [43] develop normally. Again
peroxisome proliferation is noticed in liver. Hepatic expression of
SCP2 is upregulated, especially in females. Serum and liver lipid levels
were altered in a gender-regulated manner: lower fasting serum tri-
glycerides and liver cholesterol in males. Upon treatment with phytol,
hepatic phytanic acid levels increase several fold. As observed in the
Scpx/Scp2 knockout mice, pristanic acid and 2E-pristenic acid accu-
mulate as well. This is accompanied by loss of hepatocytes, fatty vac-
uolation and liver inﬂammation. Apparently, in wild type adult
females, expressing lower levels of SCPx [44], phytol treatment is
also toxic [45].
2.5. Thiolase deﬁciency
Consistent with the redundancy of thiolases, mice lacking isoform
B of ACAA1 (strain C57BL/6 J) [46] exhibit no detectable phenotype.
No compensatory upregulation of other thiolases (isoform A; SCPx)
was found. Further analysis (but in Sv129 strain) showed a drop in
the hepatic triglyceride content and increased levels of C20:3, C20:5
and C22:5, both in liver and plasma [47]. Upon treatment with
Wy14,643, induction of peroxisomal β-oxidation was less than in
wild type mice and liver triglyceride levels increased although ex-
pression of PPARα-targets including the peroxisomal β-oxidation en-
zymes ACOX1 andMFP1, was increased. Furthermore, upregulation of
FAS and SCD1 by WY14,643 was higher in the mutants than in the
controls. In contrast, enzymes involved in cholesterol biosynthesis
were upregulated in wild type but not in Acaa1 knockout mice. The
latter was not due to a defective SREBP2 signaling [48]. It is unclear
however how ACAA1 isoform B controls these processes.
2.6. AMACR deﬁciency
Given the presence of two targeting signals on AMACR, the gene
defect affects both mitochondrial and peroxisomal AMACR in the
knockout mice [49]. In bile, serum and liver, C27 bile acid precursors
accumulate and C24 bile acid levels are lowered by 50%. The mice
are however, symptomless, probably because intestinal lipid and fat
soluble vitamin absorption is not affected despite the bile acid
changes. Hepatic MFP1 mRNA levels are increased 3-fold. MFP1 can
handle C27 bile acids (24S,25R-stereoisomer, formed via CYP3A11Table 2
List of mouse models with combined PTS1 and PTS2 import defects.
Mouse gene Model Main symptoms
Pex2 General
deletion
Embryonic lethality — 6 weeks surviva
Cerebellar and neocortical defects
cholestasis, steatosis and steatohepati
Pex5 General
deletion
Hypotonic, neonatal death
Impaired neuronal migration
Pex5-loxP Liver
alfp-cre
Steatosis
Liver
albumin-cre
Steatosis, ﬁbrosis, carcinogenesis
Brain
nestin-cre
Demyelination, inﬂammation, axon lo
Neurons
NEX-cre
No obvious symptoms
Astrocytes
Gfap-cre
No obvious symptoms
Oligodendrocytes cnp-cre Axonal degeneration
subcortical demyelination
Sertoli
AMH-cre
Infertile
testis degeneration
Pex13 General
deletion
Neonatal death
Hypotonia
Pex13-loxP Brain
nestin-Cre
Cerebellar formation
impaired reﬂex and motor developmeand CYP46A1), explaining the presence of C24 bile acids. Upon phytol
feeding, AMACR deﬁcient mice become sick with hepatomegaly, lob-
ular accumulation of lymphocytes and degeneration of hepatocytes,
and the amount of epididymal fat is reduced. Although serum levels
of phytanic and pristanic acid are increased, motor coordination and
muscular performance are not affected, which is in contrast to pa-
tients with racemase deﬁciency.
2.7. Other mouse models related to peroxisomal β-oxidation
PMP22, encoded by Pxmp2, is one of the most abundant integral
peroxisomal membrane proteins [50] and forms a non-selective
pore [17]. Based on this property, one could postulate that PMP22 al-
lows exit of α- and/or β-oxidation products. Mice lacking PMP22 de-
velop normally, however, without morphological abnormalities and
are fertile [17]. Even upon phytol supplementation, no apparent prob-
lems were noticed. On the other hand, the females do have nursing
problems due to poor development of the mammary gland but the
function of peroxisomes in this tissue is poorly understood.
Mice lacking PMP34, a putative ATP/ADP-transporter [51]
encoded by Slc25a17, do not display a particular phenotype under
standard conditions or dietary manipulations that increase the ﬂux
through peroxisomal β-oxidation. Upon feeding phytol however, he-
patic neutral lipids are increased and both phytanic acid and pristanic
acid accumulate (Van Ael E., Young S., Zwijsen A., Espeel M., Fransen
M., Baes M. and Van Veldhoven P.P., submitted).
3. Mouse models with peroxisome biogenesis defects
Three Pex genes (Pex2, Pex5, Pex13) which are necessary for the
import of both PTS1 and PTS2 peroxisomal matrix proteins were inac-
tivated in mice [52-54]. In all tissues, the residual peroxisomal ghosts
were completely incompetent to import peroxisomal enzymes. The
phenotypes of the mice were very similar although some differences
in disease severity and survival were observed which might be relat-
ed to diverse genetic backgrounds. Besides the generalized knock-
outs, also cell type selective knockouts were generated by using
Pex5-loxP and Pex13-loxP and appropriate Cre-expressing mice. Al-
though these are not real disease models, they are instrumental to de-
cipher the function of peroxisomes in particular cell types and tissues.
We review here the pathologies in liver, brain and testis of theseBiochemical abnormalities Human counterpart References
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phenotype of Pex7 knockout mice with a partial biogenesis defect,
we refer to the chapter by Brites et al. in this issue [55].
3.1. Peroxisome deﬁciency in liver
The consequences of peroxisome inactivation in liver were studied
in generalized Pex2 and Pex5 knockout mice and in mice with selec-
tive inactivation of Pex5 in hepatocytes. The latter were achieved by
breeding Pex5-loxPmice with either α-foetoprotein-Cremice resulting
in peroxisome inactivation during fetal development (denoted as Afp-
Pex5−/− mice) [56] or with albumin-Cre mice giving rise to peroxi-
some deﬁcient hepatocytes from the ﬁrst postnatal week on (denoted
as L-Pex5−/− mice) [57].
In peroxisome deﬁcient livers, the expected metabolic anomalies
were found including increased C27/C24 bile acid ratios [57,58], in-
creased VLCFA levels [52,53], plasmalogen depletion [53], reduced
levels of docosahexaenoic acid, accumulation of branched chain
fatty acids after supplementing the diet with phytol (Van Veldhoven
and Baes, unpublished observations), impaired dicarboxylic acid oxi-
dation in cultured hepatocytes [28]. In hepatocyte selective peroxi-
some knockouts, VLCFA and plasmalogen levels were unaltered
likely because of intact peroxisomal activity in other tissues. This is
at variance with the situation in brain (see below) where local loss
of functional peroxisomes in Nestin-Pex5 knockout mice does affect
VLCFA and plasmalogen levels [59]. The difference could be due to
the peroxisome metabolizing capacity of other cell types within the
tissue and/or the transfer of the peroxisomal metabolites from or sub-
strates to other tissues. Furthermore, a number of indirect conse-
quences of hampered peroxisomal metabolism were observed
including altered cholesterol and fatty acid/triglyceride homeostasis,
mitochondrial anomalies, activation of the unfolded protein response
in the ER. The different mouse models were, however, not uniformly
affected, likely due to variations in the time point of peroxisome inac-
tivation in combination with differences in the dietary lipid intake ofInactive
peroxisome
metabolism
Cholestasis
Steatosis
Hepatosteatitis
Fibrosis
Carcinogenesis
Peroxisomal β-oxidat
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Fig. 2. Overview of metabolic abnormalities reported in liver of mice with peroxisome biog
peroxisome inactivity such as bile acids, a number of secondary metabolic deregulations occ
metabolism. Together this results in steatosis and steatohepatitis.the mice. Morphologically, the metabolic abnormalities caused liver
enlargement, cholestasis, steatosis developing into steatohepatitis
and ﬁbrosis [57,58,60]. This is in good agreement with ﬁndings in
Zellweger syndrome patients. An overview of metabolic abnormali-
ties in peroxisome deﬁcient hepatocytes is given in Fig. 2.
At birth, livers of Pex2 and Pex5 generalized knockout mice
appeared normal although mitochondrial anomalies were already
observed [52,53]. Whereas Pex5−/− mice died within 24 h, a few
Pex2−/− mice survived 6 weeks allowing to further investigate the
liver phenotype. During the ﬁrst postnatal week, Pex2−/− livers be-
came increasingly cholestatic and steatotic and severe steatorrhea
developed [58]. This was also observed in hepatocyte selective
(Afp-Pex5−/−) Pex5 knockout mice [56], which presented with
pale/yellow livers and were extremely growth retarded. During
this time period, the majority of bile acids in bile, liver and plasma
of Pex2−/− mice consisted of unconjugated C27 bile acids and the
total bile acid concentration in bile was less than 3% of that in con-
trols [58]. The expression of several bile acid transporters was dys-
regulated leading to increased concentrations of primarily
unconjugated bile acids in plasma [58]. Subsequently, hepatic cho-
lestasis diminished accompanied by a reduction in stool fat content,
but Pex2−/− hepatocytes became hyperplastic and were often
hypervacuolated which later appeared to be ER dilations [61]. The
lipid accumulations persisted but in addition steatohepatitis devel-
oped, with a mixed neutrophilic/lymphocytic inﬂammatory inﬁl-
trate [58]. Because treatment of a few Zellweger patients had
shown clinical improvements, Pex2−/− mice were also supplemen-
ted with unconjugated C24 bile acids from postnatal day 1 [58].
The predominant species in bile were now unconjugated (muri)
cholic acids whereas in treated control mice almost all bile acids
were conjugated. This therapy alleviated the cholestasis, normalized
the steatorrhea, prevented the development of steatohepatitis and
allowed a larger subset of Pex2 mutants to survive until the age
of 6 weeks. However, bile acid supplementation aggravated steato-
sis and worsened mitochondrial and cellular damage. L-Pex5−/−ion
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not develop cholestasis, neither steatorrhea even when fed a high
fat diet. This was likely related to the fact that although C27/C24
was increased, conjugated C24 bile acids still reached 50% of levels
in wild type mice (Peeters and Baes, unpublished observations).
Also anomalies of cholesterol homeostasis were observed in liver
and other tissues of Pex2−/− mice. The mRNA, protein and activity
levels of cholesterol synthesizing enzymes were increased in liver
which led to enhanced cholesterogenesis from acetate in vivo [60].
This was orchestrated by an upregulation of the SREBP2 pathway,
the key regulator of cellular cholesterol homeostasis. Surprisingly,
cholesterol levels in liver and in plasma were markedly reduced.
Whether or not peroxisomes harbor cholesterol synthesizing en-
zymes has been intensively debated [62-64]. However, the ﬁndings
of perturbed cholesterol levels and cholesterol synthesizing activity
in peroxisome deﬁcient livers does not seem to be a direct conse-
quence of the putative cholesterol synthesizing capacity of peroxi-
somes because opposite changes than those observed in liver were
found in brain and kidney [60]. Furthermore, these data were not
consistent with ﬁndings in L-Pex5−/− mice in which peroxisomes
were selectively inactivated in hepatocytes in the postnatal period.
Normal levels of cholesterol and of transcripts of cholesterol synthe-
sizing enzymes were found in adult L-Pex5−/− livers, whereas
SREBP2 expression was signiﬁcantly decreased [65]. Also the fact
that bile acid feeding of Pex2−/−mice reversed cholesterol synthesiz-
ing enzyme expression to an important extent and normalized hepat-
ic and plasma cholesterol levels [58], indicated that the anomalies
might be primarily due to the cholestatic phenotype.
It was further shown that peroxisome deﬁciency activates he-
patic endoplasmic reticulum (ER) stress pathways in Pex2−/−
mice, especially the integrated stress response mediated by PERK
and ATF4 signaling [61]. Also in adult PEX5 deﬁcient hepatocytes,
evidence for activation of unfolded protein response pathways
was found by microarray analysis including up regulation of ATF3,
ATF4, ATF6 and CHOP [66]. It was suggested that in Pex2−/− mice
oxidative radicals along with other metabolic derangements acti-
vate the ER stress response which in turn creates oxidative stress.
In fact, in view of the recent ﬁndings that PPARα activation triggers
the ER stress response in Acox1 knockout mice by inducing p8 [25];
this could also be the underlying mechanism in Pex2−/− and
Pex5−/− knockout hepatocytes.
Peroxisome deﬁciency in hepatocytes not only elicited abnormal-
ities in the ER, but also severe mitochondrial anomalies at the inner
membrane [67]. This seems to be a phenomenon that is conserved
in different species as it was also reported in hepatocytes of several
Zellweger patients. It is quite striking that complexes I, III and V are
severely affected whereas complex II is intact [57]. The latter complex
is peculiar for two reasons: it is only encoded by the nuclear genome
and it is not integrated in the inner mitochondrial membrane. It re-
mains unclear whether structural mitochondrial anomalies cause
functional changes or vice versa. Also, the causative link between
the peroxisomal and mitochondrial abnormalities have not been elu-
cidated yet. Of note, mitochondrial changes were never reported in
the multiple cell lines of different species with peroxisome biogenesis
disorders. Furthermore, in other adult peroxisome deﬁcient tissues, in
particular brain and skeletal muscle, mitochondria appeared structur-
ally and functionally normal (Baes M, unpublished observations).
Therefore, the negative impact of peroxisomal inactivity on mito-
chondrial ATP production might be restricted to hepatocytes. Inter-
estingly, this is a cell autonomous phenomenon as mitochondria are
normal in the few hepatocytes of L-Pex5 knockout mice that still con-
tain peroxisomes.
The impairment of oxidative phosphorylation had a number of
consequences. First, it was shown that ATP production came primar-
ily from glycolysis in cultured L-Pex5−/− hepatocytes [57]. More de-
tailed studies revealed that a coherent metabolic adaptationprogram is activated in peroxisome deﬁcient hepatocytes in which
anabolic pathways such as gluconeogenesis, glycogen synthesis and
lipogenesis are down regulated whereas catabolic pathways includ-
ing glycolysis and fatty acid oxidation are enhanced [28,65,66]. This
is orchestrated by AMPK which is activated by an increased AMP/
ATP ratio. Strikingly, PGC-1α expression and activity was strongly
down regulated, which might also contribute to reduced gluconeo-
genesis. In fact, the simultaneous suppression of PGC-1α and activa-
tion of AMPK is a novel paradigm which is in contradiction with
current insights that AMPK stimulates PGC-1α in normal liver [66].
Taken all together, the absence of functional peroxisomes in hepa-
tocytes has a vast direct and indirect impact on metabolic homeosta-
sis. When peroxisomes are deﬁcient in the ﬁrst postnatal week,
cholestatic liver disease and steatorrhea develop, due to extremely
few mature conjugated bile acids in combination with the lipid rich
diet of suckling mice. When peroxisomes are eliminated at later
stages, levels of mature conjugated bile acids are much higher but
livers have to cope with chronic PPARα activation, impairment of mi-
tochondrial ATP production and ER stress.
3.2. Selective inactivation of peroxisomes in brain
As previously reviewed [1,2,68], peroxisome biogenesis defects in
men and in mice are characterized by cortical neuronal migration de-
fects, illustrating the importance of normal peroxisomal metabolism
for brain formation. In cerebellum, which develops postnatally in
mice, multiple defects were documented in longer surviving Pex2
mutants and in mice with conditional ablation of Pex5 or Pex13 in
all neural cells. This included delayed formation and even persistent
absence of certain cerebellar ﬁssures, impaired migration of granule
cells, abnormalities in Purkinje cell development and alineation, and
increased apoptotic cell death [56,69,70]. In this section we rather
focus on the myelin phenotype and degenerative processes of perox-
isome deﬁcient mouse brain. These features were ﬁrst studied in Nes-
tin-Pex5 knockout mice [59]. The Nestin promoter drives Cre
recombination of the Pex5 gene in all neural progenitor cells, resulting
in peroxisome deﬁciency in neurons, astrocytes and oligodendrocytes
from midgestation whereas microglia, endothelial cells and ﬁbro-
blasts are spared from peroxisome deletion. In order to further deﬁne
the importance of peroxisomes in the three neural cell types, neuron-,
astrocyte- and oligodendrocyte selective Pex5 knockout mice were
subsequently created [71,72].
Nestin-Pex5−/− mice are indistinguishable from wild type mice at
birth but from the ﬁrst week they develop a signiﬁcant growth retar-
dation continuing into adulthood. At 3 weeks, the cytoarchitecture of
the cortex appears normal but in cerebellum the developmental
problem persists: Purkinje cells are not aligned and less arborised
resulting in a thinner molecular layer. These mice show a progressive
decline in motor and cognitive abilities, become lethargic by the age
of 4–5 months and always die before the age of 6 months.
With regard to myelin, there is evidence for both developmental
and degenerative abnormalities. Hypomyelination is obvious in cere-
bellum during the second and third postnatal week [73] pointing to a
problem with the formation of myelin. This was very comparable to
the features in Gnpat knockout mice [74] but whereas Gnpat mutants
displayed only a mild loss of myelin in cerebellum and cortex in sub-
sequent months, Nestin-Pex5 mice showed drastic demyelination in
all brain regions [73]. As in patients with mild peroxisome biogenesis
disorders who develop regressive changes, demyelination in cerebel-
lum and brain stem preceded major myelin loss in corpus callosum of
Nestin-Pex5−/−mice [73]. Loss of myelin was accompanied by the ac-
tivation of microglia (Fig. 3), often developing a macrophage pheno-
type, and subsequently by astrogliosis. The inﬂammatory status was
also conﬁrmed by increased expression of pro-inﬂammatory markers
[72,73]. Importantly, throughout the brain, axons are damaged which
is followed by very extensive axon loss but there is no evidence for
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mentioned are the accumulation of droplets containing neutral lipids
which are particularly concentrated in ependymal cells and in astro-
cytes in cerebellum [59], similar to the observations inMfp2 knockout
mice.
To investigate whether the neurodegenerative phenotype origi-
nates from the loss of peroxisomal function in a particular brain cell
type, additional cell type selective Pex5 knockouts were analyzed. In-
activation of peroxisomes in forebrain projection neurons (NEX-
Pex5−/−mice) did not cause an obvious phenotype as all mice survive
for two years, and there is no evidence for loss of myelinated axons or
glial activation [72]. This is in line with the fact that peroxisomes are
underrepresented within axons [75]. Similarly, loss of peroxisomes
from astrocytes in Gfap-Pex5−/− mice did not impair survival or mo-
toric function. Neutral lipid accumulations did however occur as in
Nestin-Pex5−/− and Mfp2−/− mice [31]. As these droplets were al-
ways located in astroglia and in ependymal cells, this appears to be
a cell autonomous consequence of the peroxisomal β-oxidation de-
fect, analogous to the situation in Sertoli cells (see below). Based on
fatty acid proﬁle analysis, the accumulating fatty acids in brain are
primarily ubiquitous C16 and C18 chains which are supposed to be
substrates for mitochondrial β-oxidation. Thus, peroxisome depletion
in astroglia disturbs homeostasis of lipids which are not expected to
be metabolised by peroxisomes. However, these accumulating lipids
do not have an obvious impact on neurological function.
Loss of peroxisomes from oligodendrocytes did cause a severe
phenotype in the CNS which resembles that of Nestin-Pex5−/− mice,
encompassing demyelination, axonal loss and neuroinﬂammation,
but which is delayed in time [71,75]. Although it may be a logical ex-
pectation that peroxisome loss from oligodendrocytes affects axons
by virtue of a destabilization of myelin, there is growing evidence
that peroxisomal metabolism might contribute to a trophic role of ol-
igodendrocytes on axons independent of myelin. Indeed, both in Nes-
tin-Pex5−/− and in CNP-Pex5−/− mice, ultrastructural analysis
revealed that several axons degenerate despite a normal appearing
myelin sheet. The recent ﬁnding that peroxisomes are abundant in
paranodes, which are important sites of axon–glial interaction is
also in line with this potential metabolic support by oligodendroglial
peroxisomes [75]. CNP-Pex5−/−mice also showed a phenotype in the
peripheral nervous system, presenting as a neuropathy with impaired
motor nerve conductance and muscle weakness. Morphologically,
this was associated with swellings at the paranodes which are ﬁlled
with vesicles [75].
Our insights on the metabolic causes of the degenerative brain
phenotype remain very limited. The classic parameters of peroxisome
dysfunction, i.e. accumulation of VLCFA and deﬁciency of plasmalo-
gen levels, are found in the different conditional Pex5 knockout
mouse models except in NEX-Pex5−/− mice. This illustrates that per-
oxisomes in neurons seem to only marginally contribute to metabo-
lism in brain, whereas peroxisomes in both astrocytes and
oligodendrocytes have an essential role. A few additional consider-
ations can be made. First, although plasmalogen deﬁciency does
cause a severe brain phenotype (see chapter by P. Brites) [55], it
does not account for extensive demyelination and neuroinﬂamma-
tion as observed in Nestin-Pex5−/−mice [73]. Second, the importance
of VLCFA elevation remains obscure. As illustrated by symptomless
GFAP-Pex5−/− and Abcd1−/− mice the mere increase of C26:0 levels
is not sufﬁcient to trigger an inﬂammatory demyelinative phenotype
in the brain and other permissive factors seem to be necessary. A po-
tential contributing factor could be oxidative stress, as this is knownFig. 3. Inﬂammation, demyelination and axon loss in Nestin-Pex5 knockout mice.(A–B, E–F)
F4/80 (green) whereas myelin is stained using antibodies to the ubiquitous myelin protein
(F) of 5-month-old Nestin-Pex5 knockout mice. (C-D,G-H) The abundance of axons, stained
strongly reduced in brain stem (D) and corpus callosum (H) of these mice.to be involved in other neurodegenerative diseases and was reported
to play a role in the AMN phenotype of Abcd1−/− mice (see chapter
by A. Pujol)[76]. In Abcd1−/− ﬁbroblast cultures, C26:0 was shown to
trigger oxidative damage to proteins and lipids. Also in cultured neu-
rons of Nestin-Pex13−/− mice, increased production of superoxide
radicals but not of hydrogen peroxide or peroxide radicals was ob-
served [70]. This was however independent of C26:0 as this VLCFA
did not accumulate in brain of these mice. Therefore, the precise
role of C26:0 and oxidative stress in the neurodegenerative phenotype
will need to be further established. In view of the analogies of the
neurodegenerative phenotype of Mfp2 and Nestin-Pex5 knockout
mice, it is likely that metabolic factors resulting from deﬁcient β-
oxidation play a crucial role in the pathogenesis. However, besides
VLCFA, the number of known substrates of peroxisomal β-oxidation
in brain is rather limited. For example, although the turnover of cho-
lesterol in brain is quite high, there is currently no evidence for local
bile acid formation. One generally assumes that this applies also to di-
carboxylic acids, most likely because of the paucity of studies. Omega-
oxidation of long chain (un)saturated fatty acids is however higher in
rat brain homogenates than in liver homogenates [77]. Also PUFAs
can be converted to dicarboxylic acids, at least in the cerebral vascu-
lature [78]. The potential pathogenicity of dicarboxylic fatty acids is,
however, not supported by the normal neurological phenotype
of mice lacking MFP1, necessary for the degradation of these
compounds.
Other much more studied candidates are eicosanoids, in particular
as they are important inﬂammatory mediators. However, it should be
kept in mind that the primary inactivation of prostaglandins and leu-
kotrienes occurs in other cell compartments, and it is not known
whether the chain shortening by peroxisomal β-oxidation occurs in
brain or in the periphery. Furthermore, despite strong similarities in
lifespan and brain phenotype between Mfp2 and Nestin-Pex5 knock-
out mice, there are also important differences in the age of disease
onset and in severity of myelin abnormalities, indicating that addi-
tional factors, possibly a lack of plasmalogens, contribute to the
early phenotype of peroxisome deﬁciency in brain. A potential syner-
gizing effect of peroxisomal β-oxidation and ether lipid synthesis de-
ﬁciency is supported by the more severe phenotype of Abcd1/Pex7
double knockouts as compared to the single knockouts [79] (see
also chapter by Brites et al. in this issue [55]). To resolve this, an
unbiased metabolic proﬁle is needed allowing to identify metabolites
as potential pathogenic factors.
3.3. Selective inactivation of peroxisomes in Sertoli cells
Peroxisomes play a pivotal role in the testis as illustrated by the
impaired spermatogenesis in patients with mild PBDs [80]. The occur-
rence of these organelles in testicular cell types was previously
underestimated, but it is now well established that peroxisomes are
present in all cell types of this tissue with the exception of mature
spermatozoa [81]. However, an important diversity in enzymatic con-
tent was observed with high expression of enzymes and transporters
involved in β-oxidation in Sertoli cells and an enrichment of catalase
in Leydig cells. Remarkably, not only the absence of peroxisomal β-
oxidation is deleterious for male fertility, as shown in Mfp2−/− mice
but also the inability to synthesize ether lipids [82,83] (see also chap-
ter in this issue by P. Brites et al. [55]).
The phenotype of lipid accumulations in Sertoli cells observed in
Mfp2−/− mice was recapitulated in Amh-Pex5 knockout mice [34].
The Amh promoter exlusively drives Cre expression in Sertoli cellsActivated microglia, a sign of an inﬂammatory response, are visualized by staining with
MBP (red). Note the disappearance of myelin in brain stem (B) and in corpus callosum
with the SMI31 antibody (green) which recognizes phosphorylated neuroﬁlaments, is
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the basal membrane of Sertoli cells, pointing out that this lipid imbal-
ance originates in Sertoli cells and is not a consequence of aberrant
spermatogenesis [34]. However, the peroxisomal metabolites that
perturb lipid homeostasis in Sertoli cells still need to be identiﬁed
and the pathological role of these accumulating lipids need to be elu-
cidated. It is quite striking that the neutral lipid accumulations in
brain do not seem to be harmful, as shown by normal health of
Gfap-Pex5 knockout mice, whereas they appear to be destructive in
testis.
4. Concluding remarks
The phenotype of mouse models with peroxisomal β-oxidation
and peroxisome biogenesis defects underscores the essential role of
these organelles for the homeostasis in liver, brain and testis. In
liver, impaired peroxisomal β-oxidation affects bile acid homeostasis,
although several backup mechanisms seem to be operative to gener-
ate mature bile acids. Only in lactating mice with a complete lack of
peroxisomal β-oxidation, this resulted in steatorrhea and cholestasis.
The essential contribution of this pathway to degrade branched chain
fatty acids could only be studied in mice supplemented with phytol.
Several interruptions of peroxisomal β-oxidation cause activation of
PPARα signaling which impacts on other metabolic pathways. Fur-
thermore, the complete absence of peroxisomal function in hepato-
cytes affects mitochondrial and ER functions which have indirect
repercussions on fatty acid, cholesterol and carbohydrate homeosta-
sis. Male fertility strongly depends on intact peroxisomal function.
Both Leydig and Sertoli cells were shown to be affected by impaired
peroxisomal β-oxidation. In brain, peroxisomes are indispensable
for the maintenance of myelinated axons. Of all peroxisomal β-
oxidation enzymes, only inactivation of MFP2, which has the broadest
spectrum of substrates, was shown to cause neurodegeneration and
inﬂammation. However, the total ablation of peroxisomal function
leads to a more aggressive loss of myelin and axons, indicative that
additional factors contribute to the demise of CNS integrity. Interest-
ingly, peroxisomal function is of particular importance in oligoden-
drocytes, possibly exerting a direct trophic role on axonal integrity.
Given the availability of Pex5/13-loxP mice and multiple cell type se-
lective Cre expressing mice, many other investigations can be initiat-
ed. A potential drawback of this approach is that metabolites can be
shuttled between peroxisome containing and peroxisome deﬁcient
cell types, possibly masking the importance of peroxisomes in the lat-
ter cells.
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